Research Topics
| H S SaderSummaryCountry: Brazil Publications
| Collaborators
|
Detail Information
Publications
Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance ProgramH S Sader
Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, SP, Brazil
Braz J Infect Dis 5:200-14. 2001..Thus, regional surveillance programs are essential to guide empirical therapy and infection control measures...
Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patternsHelio S Sader
Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Diagn Microbiol Infect Dis 44:281-8. 2002..National and international surveillance programs as a guide to focusing intervention strategies should assist in the control of escalating antimicrobial resistance in this geographic area...
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centersHelio S Sader
Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Diagn Microbiol Infect Dis 44:273-80. 2002..In summary, resistance to most antimicrobial agents for a number of species implicated in bacteremia, especially among Gram-negative rods, has reached worrisome levels and continues to increase...
Antimicrobial activity of linezolid against Gram-positive cocci isolated in BrazilH S Sader
Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
Braz J Infect Dis 5:171-6. 2001..The excellent in vitro Gram-positive activity by linezolid, in this study, indicate that this compound may represent an important therapeutic option for the treatment of infections caused by these pathogens in Brazil...
Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agentsH S Sader
Division of Infectious Diseases, Universidade Federal de Sao Paulo Escola Paulista de Medicina, Sao Paulo, Brazil
Drugs 61:553-64. 2001..However, when compared with the parenterally administered compounds, the oral agents seem to lose some in vitro antibacterial activity, especially against P. aeruginosa...
Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance studyH S Sader
Division of Infectious Diseases, Federal University of Sao Paulo, Rua Botucatu, 740, Sao Paulo SP, 04023 063 Brazil
Braz J Infect Dis 5:21-31. 2001..These results define the role of quinupristin/dalfopristin in Latin American medical centers and provide a benchmark for future in vitro comparisons...
Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98)H S Sader
Federal University of Sao Paulo, Medical School of Medecine, Sao Paulo, Sao Paulo, Brazil
Braz J Infect Dis 4:245-54. 2000..The newer fluoroquinolones show an excellent potency and spectrum against pathogens causing community acquired respiratory infections in Latin America...
Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999A C Gales
University of Iowa College of Medicine, Iowa City, Iowa, USA, and Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Clin Infect Dis 32:S104-13. 2001..maltophilia isolates observed in this study emphasize the importance of local surveillance in determining the most adequate therapy for acinetobacter and S. maltophilia infections and the possible clonal, epidemic nature of occurrence...
Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance programA C Gales
Universidade Federal de Sao Paulo, Division of Infectious Diseases, Department of Medicine, Sao Paulo, Brazil
J Chemother 16:323-8. 2004..5%) and varied widely (10.0 to 48.9%) among the monitored Latin American medical centers. Mupirocin resistance rates appear to be increasing and routine monitoring for potential resistance seems prudent...
Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactamH S Sader
Special Clinical Microbiology Laboratory, Department of Infectious and Parasitic Diseases, Universidade Federal de Sao Paulo, Brazil
Braz J Infect Dis 4:22-8. 2000..3% to 98.2% susceptibility). In sum, piperacillin/tazobactam was more active against all Gram-negative species than the other two combinations, with the exception of A. baumannii, and showed similar activity against Gram-positive cocci...
In vitro antimicrobial activity of linezolid tested against vancomycin-resistant enterococci isolated in Brazilian hospitalsA O Reis
Division of Infectious Diseases, , Rua Botucatu 740, , SP 04023-063, Brazil
Braz J Infect Dis 5:243-51. 2001..faecium and E. faecalis among Brazilian hospitals. The results of this study indicate that linezolid is an appropriate therapeutic option for the treatment of vancomycin-resistant enterococci infections in Brazil...
In vitro antimicrobial activity of the aminoglycoside arbekacin tested against oxacillin-resistant Staphylococcus aureus isolated in Brazilian hospitalsJ C Cordeiro
Special Clinical Microbiology Laboratory, Division of Infectious Diseases, , SP, Brazil
Braz J Infect Dis 5:130-5. 2001....
Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002C Mendes
Fleury Medical Diagnostic Centre, Sao Paulo, Brazil
Clin Microbiol Infect 10:521-6. 2004..Levofloxacin, a fluoroquinolone prescribed widely for respiratory tract infections, continued to show potent activity against key respiratory pathogens...
IMPs, VIMs and SPMs: the diversity of metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospitalH S Sader
Laboratorio Alerta e Laboratorio Especial de Microbiologia Clínica, Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Clin Microbiol Infect 11:73-6. 2005..MBL production was detected in 36 isolates (19.7% of the entire collection; 43.9% of the imipenem-resistant isolates) and the MBLs included SPM-1-like (55.6%), VIM-2-like (30.6%) and IMP-1-like (8.3%) enzymes...
Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infectionA R Marra
Universidade Federal de Sao Paulo, Escola Paulista de Medicina, Disciplina de Doencas Infecciosas e Parasitarias, Rua Botucatu, 743, 7 andar, Vila Clementino, CEP 04023 062, Sao Paulo, SP, Brazil
Int J Infect Dis 10:56-60. 2006..For hospitals with a high prevalence of strains producing this enzyme, there is no reference material to show whether the use of the E-test method for their detection, which can be quite expensive, is actually required...
Screening of antibacterial extracts from plants native to the Brazilian Amazon Rain Forest and Atlantic ForestI B Suffredini
Laboratório de Extração, Universidade Paulista, Sao Paulo, SP, Brasil
Braz J Med Biol Res 37:379-84. 2004..The most active fractions are being fractionated to identify their active substances. Higher concentrations of other extracts are currently being evaluated against the same microorganisms...
Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unitH S Sader
Department of Infectious Disease, Paulist School of Medicine, Sao Paulo, Brazil
Diagn Microbiol Infect Dis 17:13-8. 1993..The chrDNA fingerprinting proved to be versatile and precise for epidemiologic investigations of P. aeruginosa infections...
Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patientsS Silbert
Laboratório Especial de Microbiologia Clínica, Disciplina de Doencas Infecciosas e Parasitarias, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
J Clin Microbiol 39:3976-81. 2001..aeruginosa for long periods of time. In addition, the finding of several different genotypes in the same patient suggests that the colonizing strain may occasionally be replaced...
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centresA C Gales
Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Clin Microbiol Infect 11:95-100. 2005..and Listeria spp. Dalbavancin may provide an important therapeutic option for Gram-positive infections, excluding those caused by enterococci with VanA-type resistance...
Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004)A C Gales
Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
Clin Microbiol Infect 12:315-21. 2006..4% susceptible), and was very limited (MIC50, > 8 mg/L) against Burkholderia cepacia (11.8% susceptible), Serratia spp. (5.4% susceptible), indole-positive Proteus spp. (1.3% susceptible) and Proteus mirabilis (0.7% susceptible)...
Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?A C Galles
Laboratório ALERTA, Universidade Federal de Sao Paulo, Brazil
J Chemother 20:38-42. 2008..5% susceptible by published breakpoint criteria) and moxifloxacin (MIC(90), 2 micro g/ml) MIC results was observed indicating that moxifloxacin could be further evaluated as a therapeutic option for S. maltophilia infections...
In vitro activity of ampicillin-sulbactam against clinical multiresistant Acinetobacter baumannii isolatesA C Gales
Division of Infectious Diseases, , Escola Paulista de Medicina, Brazil
J Chemother 8:416-9. 1996..baumannii; however, further studies are necessary to evaluate the clinical role of this compound for the treatment of severe infections...
Update on the cefdinir spectrum and potency against pathogens isolated from uncomplicated skin and soft tissue infections in North America: are we evaluating the orally administered cephalosporins correctly?Ronald N Jones
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 55:351-6. 2006..Cefdinir should be considered as a viable option for the therapy uSSTI caused by indicated species...
Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA)Paul R Rhomberg
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 56:57-62. 2006....
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004)Amy A Watters
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Antimicrob Chemother 57:914-23. 2006....
Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003)Kelley A Fedler
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 55:157-64. 2006..pneumoniae (refractory otitis media) and P. aeruginosa (cystic fibrosis associated pneumonia)...
Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American Hospitals: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)Michael A Pfaller
Department of Pathology and Epidemiology, University of Iowa College of Medicine and College of Public Health, Iowa City, IA 52242, USA
Diagn Microbiol Infect Dis 56:63-8. 2006..isolated in North American medical centers. Continued resistances surveillance monitoring will be necessary to assess the effectiveness of widely used broad-spectrum antimicrobials as novel resistance mechanisms emerge...
Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)Ronald N Jones
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 54:149-53. 2006..Dalbavancin wild-type MIC distributions remain unchanged compared with prior sampled years (2002-2003) in the USA...
Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002)Ana C Gales
Departamento de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, SP 04025 010, Brasil
Mem Inst Oswaldo Cruz 100:571-7. 2005..Since selection of the most appropriate antimicrobial agents for testing and reporting has not been established by the NCCLS for many of NF-GNB species, results from large multicenter studies may help to guide the best empiric therapy...
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion testsRonald N Jones
JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Antimicrob Chemother 56:1047-52. 2005..CONCLUSIONS: PPI-0903M was generally bactericidal against tested species, and the MIC results were stable across numerous susceptibility test condition changes...
Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003)Helio S Sader
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 52:265-73. 2005..Continued resistance surveillance is critical to monitor the effectiveness of widely used parenteral antimicrobial agents such as cefepime...
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unitHelio S Sader
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 52:203-8. 2005..aeruginosa) isolated from ICU patients and may represent an excellent option for the treatment of infections in this clinical environment...
Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance programRonald N Jones
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Clin Microbiol 44:2622-5. 2006..Vancomycin test results most reliably predict dalbavancin susceptibility until validated commercial reagents become available for direct testing in clinical practice...
Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004)Ronald N Jones
JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 57:109-16. 2007..4% and 2.3%, respectively). Our results indicate that cefepime was the most broad-spectrum cephalosporin analyzed and remains a very potent alternative for the treatment of contemporary pediatric infections in North America...
Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines?Soraya S Andrade
Laboratório Especial de Microbiologia Clínica, Universidade Federal de Sao Paulo, 04025 010 São Paulo, SP, Brazil
Mem Inst Oswaldo Cruz 101:741-8. 2006..Our results highlight the need for developing specific CA-UTI guidelines in geographic regions where elevated resistance to new and old compounds may influence prescribing decisions...
Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheter-associated infectionsThomas R Fritsche
JMI Laboratories, North Liberty, IA 52317, USA
J Antimicrob Chemother 61:1092-8. 2008..We evaluated the spectrum and potency of omiganan against pathogens commonly associated with such infections...
Selection of a surrogate beta-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenemRonald N Jones
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 59:467-72. 2007....
Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infectionsHelio S Sader
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Int J Antimicrob Agents 30:514-20. 2007..1%) and imipenem in Spain (87.7%). Our results suggest that tigecycline represents a viable additional option for the empirical treatment of cSSSI in these countries...
Detection of inducible clindamycin resistance in staphylococci by broth microdilution using erythromycin-clindamycin combination wellsJana M Swenson
Antimicrobial Resistance Team, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
J Clin Microbiol 45:3954-7. 2007..After a 24-h incubation, the ERY-CC combinations of 4 and 0.5, 6 and 1, and 8 and 1.5 microg/ml correlated well with the D-zone test...
Evaluation of the susceptibility profiles, genetic similarity and presence of qnr gene in Escherichia coli resistant to ciprofloxacin isolated in Brazilian hospitalsAndrea S Pereira
Special Laboratory of Microbiology, Federal University of Sao Paulo, SP, Brazil
Braz J Infect Dis 11:40-3. 2007..The great genomic variability found among the ciprofloxacin-resistant Escherichia coli highlights the importance of the appropriate use of quinolone to restrict the selection of resistant isolates...
Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of viewDaniel Curcio
J Clin Microbiol 45:2095; author reply 2095-6. 2007
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospitalRodrigo E Mendes
Laboratório Especial de Microbiologia Clínica and Laboratório ALERTA, Division of Infectious Disease, Federal University of Sao Paulo, Sao Paulo, Brazil
Antimicrob Agents Chemother 51:2611-4. 2007..This report describes the ability of nonfermentative nosocomial pathogens to acquire and disseminate antimicrobial resistance determinants...
Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)Helio S Sader
JMI Laboratories, North Liberty, Iowa, USA
BMC Infect Dis 7:29. 2007..We evaluated the in vitro activity of this compound and selected comparator agents tested against clinical strains of staphylococci and enterococci collected in European medical centers in 2005...
In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004)Helio S Sader
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 58:27-32. 2007....
Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004)Thomas R Fritsche
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 58:19-26. 2007..These in vitro data suggest that garenoxacin warrants further clinical studies in SSTI, especially against staphylococci and streptococcal pathogens...
Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005)Michael A Pfaller
University of Iowa, Iowa City, IA 52242, USA
Diagn Microbiol Infect Dis 57:459-65. 2007..5, and 1 microg/mL for staphylococci, enterococci, beta-hemolytic streptococci, and viridans group streptococci, respectively, and no significant loss in potency was observed over the period studied...
Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum StudyJames E Ross
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Int J Antimicrob Agents 29:295-301. 2007..With MDR in Gram-positive organisms increasing in prevalence, continued surveillance of linezolid appears to be prudent practice as linezolid becomes more widely prescribed for these difficult-to-treat infections...
Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004)Lalitagauri M Deshpande
JMI Laboratories, North Liberty, Iowa, USA
Microb Drug Resist 12:223-30. 2006....
Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United StatesDouglas J Biedenbach
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Clin Microbiol 45:998-1004. 2007..Dalbavancin demonstrated excellent potency and activity (100% susceptibility at proposed breakpoints) against common causes of SSSI pathogens in this U.S. multicenter study sample...
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006)Thomas R Fritsche
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 61:86-95. 2008..These characteristics warrant continued evaluation of the agent as empiric therapy for cSSSIs, and in pneumonia, especially in those institutions/regions where MRSA and P. aeruginosa may be prevalent...
Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004)Thomas R Fritsche
JMI Laboratories, Inc, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 52:195-201. 2005..Tigecycline represents a new choice among broad-spectrum parenteral agents for the common Gram-positive and -negative pathogens producing serious infections of skin and soft tissues...
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumoniaThomas R Fritsche
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 52:187-93. 2005..Further clinical studies should consider the role that tigecycline may play in the therapy for severe respiratory tract infections, both of nosocomial and community origin...
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluationsRonald N Jones
The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Antimicrob Chemother 54:144-54. 2004..To investigate the potency of doripenem, a broad-spectrum carbapenem characterized by a wider spectrum of activity combining antimicrobial and bactericidal features of imipenem and meropenem...
Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolatesRonald N Jones
The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Antimicrob Chemother 53:804-7. 2004..To evaluate the potency of a novel peptide deformylase inhibitor, NVP PDF-713, against Gram-positive organisms having resistances to linezolid or quinupristin/dalfopristin...
Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organismsJennifer M Streit
The JONES Group/JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
J Antimicrob Chemother 53:669-74. 2004..CONCLUSIONS: Daptomycin exhibited excellent in vitro activity against a wide spectrum of Gram-positive organisms and may represent a therapeutic option for infections caused by multidrug-resistant pathogens worldwide...
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolatesJennifer M Streit
The JONES Group JMI Laboxratories, North Liberty, IA, USA
Diagn Microbiol Infect Dis 48:137-43. 2004..Some VRE were inhibited by very low dalbavancin concentrations (< or = 1 microg/ml; Van B phenotypes). Further clinical development seems warranted for this once-weekly administered agent...
Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centresPaul R Rhomberg
The JONES Group, JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Int J Antimicrob Agents 23:52-9. 2004..Most apparent were the decreasing susceptibility rates for ciprofloxacin and ceftazidime against staphylococci. Continued surveillance in these institutions appears warranted as sites of high potential emerging resistance risk...
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001)Alan H Mutnick
The JONES Group/JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
J Antimicrob Chemother 53:290-6. 2004....
In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and StreptococciHelio S Sader
The JONES Group JMI Laboratories, North Liberty, Iowa 52317, USA
Antimicrob Agents Chemother 48:53-62. 2004..In conclusion, LB 11058 demonstrated a broad antibacterial spectrum and was highly active against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci...
Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001)Ronald N Jones
The JONES Group/JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Int J Antimicrob Agents 22:551-6. 2003..Resistance surveillance among these organisms remains necessary to guide empirical antimicrobial therapy, especially for these less frequently isolated and difficult to test pathogens...
The use of molecular typing to evaluate the dissemination of antimicrobial resistance among Gram-negative rods in Brazilian hospitalsIraci Tosin
, Special Laboratory of Clinical Microbiology, , SC, Brazil
Braz J Infect Dis 7:360-9. 2003..We conclude that the ability to characterize organisms phenotypically and genotypically is a powerful epidemiologic tool and it provides unique information that is very important for multicenter surveillance programs...
Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilliHelio S Sader
The JONES Group/JMI Laboratories, North Liberty, IA, USA
Diagn Microbiol Infect Dis 47:547-50. 2003....
Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: Thomas R Fritsche
The JONES Group JMI Laboratories, North Liberty, Iowa, USA
Diagn Microbiol Infect Dis 47:435-40. 2003..These findings confirm that the newer cephalosporins (cefepime and ceftriaxone) among broad-spectrum beta-lactam agents have a spectrum of activity that remains comprehensive for the commonly isolated Gram-positive pathogens...
Contemporary re-evaluation of the activity and spectrum of grepafloxacin tested against isolates in the United StatesKelley A Gordon
The JONES Group/JMI Laboratories, North Liberty, IA, USA
Diagn Microbiol Infect Dis 47:377-83. 2003..03 microg/ml) and Legionella spp. (MIC(90), 0.5 microg/ml). These results on recently isolated organisms indicate that grepafloxacin has a sustained potency and spectrum against most clinically important and indicated pathogens...
Salmonella spp. isolates causing bloodstream infections in Latin America: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000)Ana C Gales
Laboratório Especial de Microbiologia Clínica, Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil
Diagn Microbiol Infect Dis 44:313-8. 2002....
Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activityHelio S Sader
The JONES Group JMI Laboratories, Inc, North Liberty, Iowa 52317, USA
Antimicrob Agents Chemother 48:3112-8. 2004..Kill curve experiments showed a clear pattern of bactericidal activity...
SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001Helio S Sader
Special Laboratory of Clinical Microbiology, Division of Infectious Diseases, Federal University of Sao Paulo, Sao Paulo, SP, Brazil
Braz J Infect Dis 8:25-79. 2004..This report allows the evaluation of the activities numerous antimicrobial agents against clinical isolates collected in Latin American countries...
Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)Jennifer M Streit
The JONES Group/JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IW 52317, USA
Int J Antimicrob Agents 24:111-8. 2004..Cefepime and the carbapenems (imipenem or meropenem) for Gram-negative isolates and linezolid for Gram-positive isolates, provided the broadest spectrum of in vitro activity against contemporary ICU pathogens in North America...
Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continentsHelio S Sader
JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 52:181-6. 2005..Serious infections in nosocomial environments should benefit from tigecycline use among the investigational phase 3 agents focused toward resistant strains...
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strainsHelio S Sader
JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Antimicrob Agents Chemother 49:3501-12. 2005....
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogensJennifer M Streit
The JONES Group/JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 53:307-10. 2005..In summary, dalbavancin was very active against a wide spectrum of resistant Gram-positive isolates and demonstrated greater potency than vancomycin or teicoplanin...
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanismsRonald N Jones
The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 52:71-4. 2005..016 mug/mL (with higher values for ertapenem). Doripenem appears to be a promising, potent carbapenem for parenteral use against contemporary Gram-negative bacilli producing various beta-lactamases...
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importanceThomas R Fritsche
The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317, USA
Antimicrob Agents Chemother 49:1468-76. 2005....
Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agentsSudha Pottumarthy
The JONES Group JMI Laboratories, Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Int J Antimicrob Agents 25:282-9. 2005..4%). Local and global surveillance studies of common respiratory pathogens such as S. pneumoniae remain instrumental to guide clinicians in appropriate empirical treatments and to emphasize the need for prudent antimicrobial use...
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panelsJames E Ross
The JONES Group JMI Laboratories, North Liberty, IA 52317, USA
Diagn Microbiol Infect Dis 51:219-21. 2005..0%) for on-scale results analyzed at +/-1 log2 dilution for same- and between-day comparisons. Newer and investigational fluoroquinolone agents, including gemifloxacin, can be tested with confidence using these dry-form MIC panels...
Emerging epidemic of metallo-beta-lactamase-mediated resistancesRonald N Jones
Diagn Microbiol Infect Dis 51:77-84. 2005
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilliHelio S Sader
JMI Laboratories Inc, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
Int J Antimicrob Agents 25:95-109. 2005....
Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance ProgramHelio S Sader
The JONES Group JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, USA
Int J Antimicrob Agents 25:57-61. 2005..The emergence and dissemination of mobile MbetaL-producing isolates represent an alarming factor for increasing resistance to carbapenems in several medical centres evaluated by the SENTRY Program in Latin America...
Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolatesLalitagauri Deshpande
The JONES Group/JMI Laboratories, North Liberty, IA, USA
Diagn Microbiol Infect Dis 50:73-5. 2004..BAL9141 displayed a predominant bactericidal activity against the majority of Gram-positive and -negative species, including resistant subsets, making it an attractive candidate for further development...
Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolatesHelio S Sader
The JONES Group JMI Laboratories, North Liberty, IA, USA
Diagn Microbiol Infect Dis 49:283-7. 2004..Only 0.5% of all 415 recent CA-SSTI pathogens were resistant to cefdinir (MIC, > or = 4 mg/L). Cefdinir showed a spectrum and potency comparable or superior to other orally administered beta-lactams (cephalexin)...
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003)Paul R Rhomberg
The JONES Group/JMI Laboratories, North Liberty, IA, USA
Diagn Microbiol Infect Dis 49:273-81. 2004..and Acinetobacter baumannii isolates. Continued surveillance of the carbapenem class and other broad-spectrum agents is warranted to monitor activity against pathogens causing serious infections in hospitalized patients...
Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)Ana C Gales
Division of Infectious Diseases, Universidade Federal de, Sao Paulo, SP, Brazil
Diagn Microbiol Infect Dis 44:289-99. 2002..Carbapenem-resistant P. aeruginosa, ciprofloxacin-resistant E. coli, ESBL-producing K. pneumoniae constitute serious problem in this geographic region...
